Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Balcinrenone - AstraZeneca

Drug Profile

Balcinrenone - AstraZeneca

Alternative Names: AZD-9977

Latest Information Update: 19 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Acetamides; Benzoxazines; Cardiovascular therapies; Fluorinated hydrocarbons; Small molecules; Urologics
  • Mechanism of Action Mineralocorticoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Heart failure; Kidney disorders
  • Discontinued Cardiovascular disorders; Diabetic nephropathies

Most Recent Events

  • 19 Mar 2024 AstraZeneca plans a phase III trial in Chronic heart failure (Combination therapy) in USA, Argentina, Australia, Austria, Canada, Chile, China, Colombia, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Kores, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, Vietnam (NCT06307652)
  • 22 Sep 2023 AstraZeneca completes the phase II MIRACLE trial in Chronic heart failure (Combination therapy, In adults, In the elderly) in Hungary, Belgium, Bulgaria, Canada, Czech Republic, Denmark, Germany, Italy, Japan, Lithuania, Poland, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine (NCT04595370)
  • 08 May 2023 Nuremberg Clinic initiates a phase II DapaBalci-Leap trial for Kidney disorders (Combination therapy, In the elderly, In adults) in Germany and France (PO) (NCT05884866)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top